Agenus Strategic Decision to Withdraw the BLA for Balsitilimab
October 22, 2021 0
Agenus to Withdraw BLA for Balstilimab Agenus (AGEN) announced a strategic decision to withdraw its Biologics License Application (BLA) for balstilimab, its PD-1 inhibitor. The firm stated that its decision will not change the development plans for balstilimab with regard to its combination with AGEN1181, which will . . . This content is for paid subscribers. Please click here to subscribe or here to log in.